Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

Completed

Conditions studied: Diabetic Macular Edema

In brief

A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.

Key facts

Study ID

NCT03889444

Run by

Allergan

People needed

141

Starts

2019-01-15

Expected to finish

2019-06-07

Last updated by the study team

2020-06-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant received at least two Ozurdex® implants in the study eye to treat visual impairment due to DME
• First Ozurdex® implant injection occurred after 1 January 2015
• Participant was followed-up at the site for at least 12 months after the first Ozurdex® implant in the study eye

You may not qualify if…

• Participant received Ozurdex® implants as part or during a clinical study

Where it is running

• Clinical Trials Registry Team — Irvine, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.